Next-Generation Chimeric Antigen Receptors (CAR) Targeting CD70 for the Treatment of Kidney Cancers
Abstract
Patients with kidney cancer show a high level expression of a protein called CD70. Chimeric antigen receptor T (CAR-T) is a novel approach to genetically engineer immune cells to kill cancer cells. Despite the success of CAR-T in blood cancers, there are several limitations to this approach including lack of efficacy against solid tumors and toxicities. To overcome these design limitations of current-generation CARs, we have developed a next-generation platform, designated nCAR. The main objective of our proposal is to generate a panel of nCARs targeting CD70 for the treatment of kidney cancers and to demonstrate their efficacy and safety using preclinical studies. Thus, the project s area of emphasis is to identify innovative strategies for the treatment of kidney cancer. At the end of the project period, we hope to have obtained preliminary evidence of the safety and efficacy of CD70 nCARs using preclinical studies, which will lay the foundation for confirmatory studies before the initiation of human clinical trials in 4-5 years. In the long term, the CD70 nCAR developed by this project could potentially revolutionize the treatment of kidney cancers, as a single injection of CD70 nCAR could potentially result in long-term remission, and perhaps cure, of even advanced metastatic disease. The CD70 nCAR of the current proposals could also be combined with other forms of immunotherapy and/or targeted therapies to further improve the response rate or duration of remission. The project is highly relevant to military health as military personnel are at high risk of kidney cancer due to the high prevalence of smoking among Service Members and their exposure to environmental toxins.
Document Details
- Document Type
- DoD Grant Award
- Publication Date
- Dec 28, 2022
- Source ID
- W81XWH2210148
Entities
People
- Preet Chaudhary
Organizations
- United States Army
- University of Southern California